Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028382 | 0.96 | CHRM3 (0.39) | CHRM3ALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL7025599 | 0.85 | CHRM3 (0.39) | CHRM3ALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL7113639 | 0.68 | KMT2A (0.34) | ALDH1A1KCNN4 | |
| SCHEMBL7771203 | 0.67 | MAPK1 (0.35) | CHRM3ALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL7771212 | 0.63 | CHRM3 (0.34) | CHRM3ALDH1A1CHRM2KCNN4 | |
| SCHEMBL4278959 | 0.63 | KDM4E (0.37) | ALDH1A1KCNN4 | |
| SCHEMBL20856211 | 0.63 | KMT2A (0.36) | CHRM3CHRM2CHRM1KCNN4 | |
| SCHEMBL4245314 | 0.62 | CHRM3 (0.60) | CHRM3ALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL3998747 | 0.61 | KCNN4 (0.47) | CHRM3ALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL4893317 | 0.60 | KCNN4 (0.42) | CHRM3ALDH1A1KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117669-B1 | ANTIVIRAL PURINE DERIVATIVES | UNIV CARDIFF (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | CHRM3 4722/4885ALDH1A1 1940/4885CHRM2 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.